# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Kezar Life Sciences (NASDAQ:KZR) with a Buy and maintains $20 ...
Kezar Life Sciences (NASDAQ:KZR) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of ...
Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (NASDAQ:KZR) announced today that the Center for Drug Evaluation...
Lithium market facing persistent turmoil as spot prices decline for more than a year. But asset management firm Janus Henderson...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Kezar Life Sciences (NASDAQ:KZR) with a Buy and maintains $20 ...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Kezar Life Sciences (NASDAQ:KZR) with a Buy and maintains $20 ...
Wells Fargo analyst Derek Archila maintains Kezar Life Sciences (NASDAQ:KZR) with a Equal-Weight and lowers the price target...
Kezar Life Sciences (NASDAQ:KZR) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(...